Reversal of Subchronic PCP-Induced Deficits in Attentional Set Shifting in Rats by Sertindole and a 5-HT6 Receptor Antagonist: Comparison Among Antipsychotics
The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Abstract
Currently accepted treatments for schizophrenia can effectively control positive symptoms but have limited impact on cognitive deficits in schizophrenia. The purpose of these experiments was to address this unmet need by characterizing the effects of classical and second-generation antipsychotics on cognitive impairments associated with schizophrenia. An additional aim was to characterize the part(s) of the pharmacological profile of drugs that were important to reverse deficits. Cognitive deficits were assessed using a frontally mediated attentional set-shifting task in rats that is analogous to tasks used in humans and nonhuman primates that assess executive function. Mirroring findings in patients with schizophrenia, the classical antipsychotic haloperidol was ineffective in treating set-shifting deficits induced by subchronic treatment with phencyclidine (PCP). Similarly, second-generation antipsychotics, risperidone, clozapine, and olanzapine were ineffective. In contrast, selected doses of sertindole and the 5-HT(6) receptor antagonist SB 271046 attenuated PCP-induced set-shifting deficits. Finally, the 5-HT(2A) receptor antagonist M100907 was without effect. Further examination revealed that repeated treatment (21 days) with sertindole, but not olanzapine, also was effective in reversing the executive function deficit. These data suggest that the combination of 5-HT(6) antagonistic activity and the absence of antimuscarinic activity may represent key characteristics of the pharmacological profile for improved antipsychotic drugs for schizophrenia.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In PCP-treated rats, the 5-HT6 receptor antagonist, SB 271046, and sertindole, a second generation antipsychotic that acts as an antagonist on several neurotransmitter receptors, with high affinity for the 5-HT6 receptor, reduced the PCP-induced deficit in set-shifting (Idris et al 2010, Rodefer et al 2008).”
From Prefrontal cortex executive processes affected by stress in health and disease (2018) · cites this paper as Rodefer et al 2008
Citations
Cites
What are the functional consequences of neurocognitive deficits in schizophrenia?
(1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.3.321 · Cited by 3,516 · cited 1×
“Unlike psychotic symptoms, cognitive deficits demonstrate a robust inverse association with community functioning and illness outcome (Addington and Addington, 1999; Green, 1996; Harvey et al, 1999).”
BackgroundGreen, M. F., Kern, R. S., Braff, D. L., & Mintz, J. (2000) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033430 · Cited by 2,999 · cited 1×
“However, Kraepelin’s characterization of schizophrenia from over a century ago included descriptions of cognitive deficits (Kraepelin, 1904), and these have gained greater attention in the treatment literature during the past decade (Green et al, 2000; Weinberger and Gallhofer, 1997).”
BackgroundRecent advances in the phencyclidine model of schizophrenia
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.10.1301 · Cited by 2,904 · cited 2×
“…we employed the well-validated subchronic phencyclidine (PCP)-administration paradigm (Jentsch and Roth, 1999; Cochran et al, 2003; Egerton et al, 2005; Abdul-Monim et al, 2006, 2007) to produce enduring cognitive deficits similar to those observed in schizophrenia (Javitt and Zukin, 1991).”
MethodDissociation in prefrontal cortex of affective and attentional shifts
Dias, R., Robbins, T. W., & Roberts, A. C. (1996) · Nature · doi:10.1038/380069a0 · Cited by 1,527 · cited 1×
“Indeed, different regions of prefrontal cortex mediate extradimensional attentional shifts and reversal learning (Birrell and Brown, 2000, McAlonan and Brown, 2003, Dias et al, 1996).”
BackgroundMedial Frontal Cortex Mediates Perceptual Attentional Set Shifting in the Rat
Birrell, J. M., & Brown, V. J. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-11-04320.2000 · Cited by 1,421 · cited 5×
“The set-shifting task adapted for rodents uses olfactory and tactile stimuli, rather than the visual stimuli used for testing of nonhuman primates and humans (Birrell and Brown, 2000).”
BackgroundMethodInfluentialJentsch, J. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00060-8 · Cited by 1,314 · cited 2×
“In addition, we employed the well-validated subchronic phencyclidine (PCP)-administration paradigm (Jentsch and Roth, 1999; Cochran et al, 2003; Egerton et al, 2005; Abdul-Monim et al, 2006, 2007) to produce enduring cognitive deficits similar to those observed in schizophrenia (Javitt and Zukin,…”
MethodKeefe, R. S. E. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.6.633 · Cited by 1,065 · cited 2×
“Depending on the type of cognitive domain measured, second-generation antipsychotics have been reported to produce improvement (Mortimer 1997; Meltzer and McGurk, 1999; Keefe et al, 2007), no effect (Hoff et al, 1996; Meltzer and McGurk, 1999), and impairment (Goldberg et al, 1993).”
BackgroundMethodThe Effects of Clozapine, Risperidone, and Olanzapine on Cognitive Function in Schizophrenia
Meltzer, H. Y., & McGurk, S. R. (1999) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033376 · Cited by 1,020 · cited 5×
“…et al, 2004; Remillard et al, 2005; Lee et al, 2007) or slightly effective, as measured by Wisconsin Card Sorting Test (Meltzer and McGurk, 1999; Harvey et al, 2005), and olanzapine produces effects in the same range as risperidone (Meltzer and McGurk, 1999; Bilder et al, 2002; Keefe et al, 2007).”
BackgroundMethodInfluentialVerapamil: A Review of its Pharmacological Properties and Therapeutic Use1
Singh, B. N., Ellrodt, G., & Peter, C. T. (1978) · Drugs · doi:10.2165/00003495-197815030-00001 · Cited by 832
Do Novel Antipsychotics Have Similar Pharmacological Characteristics? A Review of the Evidence
Arnt, J. (1998) · Neuropsychopharmacology · doi:10.1016/s0893-133x(97)00112-7 · Cited by 715 · cited 3×
“Clozapine has weaker DA D2 in vivo binding potency, but the selected doses examined were within behaviorally active levels, and further dose increase leads to marked sedation (see Arnt and Skarsfeldt, 1998).”
BackgroundSelf-citation
Research works printed but not linked: 1
- Rodefer JS (2006). The effects of antipsychotics on reversing PCP-induced deficits in a rodent attentional set-shifting task. Schizophr Res 81S: 130.
Cited by
Neill, J. C., Barnes, S., Cook, S., Grayson, B., Idris, N. F., McLean, S. L., Snigdha, S., Rajagopal, L., & Harte, M. K. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.07.004 · Cited by 530
“…ineffective in reversing the PCP-induced deficit, however sertindole and the selective 5-HT6 (SB-271046) and 5-HT2A (M100907) receptor antagonists did attenuate the PCP-induced impairment (Rodefer et al., 2008), which is similar to our findings using reversal learning paradigm (Idris et al. 2010).”
ResultNeural circuits subserving behavioral flexibility and their relevance to schizophrenia
Floresco, S. B., Zhang, Y., & Enomoto, T. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2008.12.001 · Cited by 298
Revel, F. G., Moreau, J.-L., Pouzet, B., Mory, R., Bradaia, A., Buchy, D., Metzler, V, Chaboz, S., Groebke Zbinden, K., Galley, G., et al. (2013) · Molecular Psychiatry · doi:10.1038/mp.2012.57 · Cited by 288
Nielsen, R. E., Levander, S., Kjaersdam Telléus, G., Jensen, S. O. W., Østergaard Christensen, T., & Leucht, S. (2015) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12374 · Cited by 270
Ventral Striatal Dopamine Modulation of Different Forms of Behavioral Flexibility
Haluk, D. M., & Floresco, S. B. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2009.21 · Cited by 195
Ketamine and phencyclidine: the good, the bad and the unexpected
Lodge, D., & Mercier, M. S. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13222 · Cited by 184
“Such chronic exposure to dissociative anaesthetics also leads to behavioural correlates of the disease (Jentsch and Roth, 1999; Wang et al., 2001; Egerton et al., 2008; Rodefer et al., 2008; Goetghebeur and Dias, 2009; Amitai and Markou, 2010; Neill et al., 2010).”
BackgroundGilmour, G., Dix, S., Fellini, L., Gastambide, F., Plath, N., Steckler, T., Talpos, J., & Tricklebank, M. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.03.015 · Cited by 184
“…D1 agonism, AMPA positive allosteric modulators, nicotinic alpha7 agonism, 5-HT2A antagonism, 5-HT2C antagonism, 5-HT6 antagonism and PDE10 inhibition (Damgaard et al., 2010; Idris et al., 2010; McLean et al., 2008, 2009a,b; Pichat et al., 2007; Rodefer et al., 2005, 2008; Thomsen et al., 2009).”
Sertindole: pharmacological and clinical profile and role in the treatment of schizophrenia
Spina, E., & Zoccali, R. (2008) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.4.5.629 · Cited by 184
“A recent experimental study in rats has suggested that the favourable cognitive profile of sertindole may be related to the combination of antagonistic activity at 5HT 6 receptors and the absence of antimuscarinic activity [20] .”
BackgroundPrefrontal cortex executive processes affected by stress in health and disease
Girotti, M., Adler, S. M., Bulin, S. E., Fucich, E. A., Paredes, D., & Morilak, D. A. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.07.004 · Cited by 176
Serotonin and decision making processes
Homberg, J. R. (2012) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2011.06.001 · Cited by 167
Amitai, N., & Markou, A. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.03.004 · Cited by 136
“The extradimensional shift phase of the set shifting task was likewise disrupted during the drug-free state after PCP administered subchronically [62,63,105,107,110,115], chronically [116], once 24 hours before testing [79], or postnatally [114,115], though not after withdrawal from subchronic ketamine treatment [140].”
Maeda, K., Lerdrup, L., Sugino, H., Akazawa, H., Amada, N., McQuade, R. D., Stensbøl, T. B., Bundgaard, C., Arnt, J., & Kikuchi, T. (2014) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.213819 · Cited by 144
“…that haloperidol is ineffective whereas risperidone, olanzapine, and clozapine show nonsignificant trends toward improved ED-shift performance, and other antipsychotics, sertindole, and quetiapine show full reversal (Rodefer et al., 2008; Goetghebeur and Dias, 2009; Nikiforuk and Popik, 2012).”
BackgroundMethodInfluentialSelf-citationEffects of chronic stress on cognitive function – From neurobiology to intervention
Girotti, M., Bulin, S. E., & Carreno, F. R. (2024) · Neurobiology of Stress · doi:10.1016/j.ynstr.2024.100670 · Cited by 210
“The 5-HT 6 receptor antagonists SB 271046 and sertindole were also shown to reduce deficits in set-shifting produced by PCP (Idris et al., 2010; Rodefer et al., 2008).”
Wallace, T. L., Callahan, P. M., Tehim, A., Bertrand, D., Tombaugh, G. C., Wang, S., Xie, W., Rowe, W. B., Ong, V., Graham, E., et al. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.171892 · Cited by 121
“Typical and atypical antipsychotic medications, which are useful in treating the positive symptoms of schizophrenia, do little to improve cognitive dysfunction in this patient population and in the extradimensional set shifting (Rodefer et al., 2008).”
BackgroundMethodInfluentialSelf-citationLeiser, S. C., Li, Y., Pehrson, A. L., Dale, E., Smagin, G., & Sanchez, C. (2015) · ACS Chemical Neuroscience · doi:10.1021/cn500340j · Cited by 110
Pharmacological Enhancement of Memory and Executive Functioning in Laboratory Animals
Floresco, S., & Jentsch, J. D. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.158 · Cited by 131
Arnt, J., Bang-Andersen, B., Grayson, B., Bymaster, F. P., Cohen, M. P., DeLapp, N. W., Giethlen, B., Kreilgaard, M., McKinzie, D. L., Neill, J. C., et al. (2010) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145710000659 · Cited by 107
“2009) and after subchronic PCP treatment, a model suggested as relevant for CIAS (Idris et al. 2010 ; Rodefer et al. 2008).”
BackgroundMethodSelf-citationGoetghebeur, P., & Dias, R. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1132-9 · Cited by 113
Attentional Set-Shifting Across Species
Brown, V. J., & Tait, D. S. (2015) · Current topics in behavioral neurosciences · doi:10.1007/7854_2015_5002 · Cited by 113
de Bartolomeis, A., Vellucci, L., Barone, A., Manchia, M., Luca, V. D., Iasevoli, F., & Correll, C. U. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108236 · Cited by 98
Snigdha, S., Horiguchi, M., Huang, M., Li, Z., Shahid, M., Neill, J. C., & Meltzer, H. Y. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.156349 · Cited by 90
“622 reasoning and problem solving, working memory, and social cognition (Stefani and Moghaddam, 2002; Abdul-Monim et al., 2007; Grayson et al., 2007; Rodefer et al., 2008; McLean et al., 2009), thus providing an animal model for related deficits in schizophrenia and the efficacy of atypical APDs to…”
BackgroundAlzheimer's disease and age-related memory decline (preclinical)
Terry, A. V., Callahan, P. M., Hall, B., & Webster, S. J. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.02.002 · Cited by 86
“…et al., 2007 SB 271046 antagonist Callahan et al., 2004; Foley et al., 2004; King et al., 2004; Loiseau et al., 2008; Marcos et al., 2008; Rodefer et al., 2008; Routledge et al., 2000 SB 357134 antagonist Rogers and Hagan, 2001; Stean et al., 2002 SB 399885 antagonist Hatcher et al.,…”
BackgroundBrigman, J. L. (2009) · Frontiers in Behavioral Neuroscience · doi:10.3389/neuro.08.002.2009 · Cited by 85
“…see Stefani and Moghaddam, 2002), T-maze spatial reversal learning (Jentsch and Taylor, 2001), extra-dimensional set-shifting (EDS; Egerton et al., 2008; Rodefer et al., 2005, 2008), and reversal learning in maze- and operant-based tasks (Abdul-Monim et al., 2006, 2007; Jentsch and Taylor, 2001).”
BackgroundMethodMcLean, S. L., Idris, N. F., Grayson, B., Gendle, D. F., Mackie, C., Lesage, A. S., Pemberton, D. J., & Neill, J. C. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881111431747 · Cited by 81
“This result is supported by several studies in other laboratories in which sub-chronic PCP also produces deficits in the EDS phase of the attentional set-shifting task, although ours is the only study to use female rats (Egerton et al., 2008; Goetghebeur and Dias, 2009; Rodefer et al., 2005, 2008).”
ResultClozapine for the treatment of schizophrenia
Fakra, É., & Azorin, J. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.709235 · Cited by 90
Lesions of the orbital prefrontal cortex impair the formation of attentional set in rats
Chase, E. A., Tait, D. S., & Brown, V. J. (2012) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2012.08141.x · Cited by 79
Gilmour, G., Arguello, P. A., Bari, A., Brown, V. J., Carter, C., Floresco, S., Jentsch, J. D., Tait, D. S., Young, J. W., & Robbins, T. W. (2012) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2012.04.006 · Cited by 87
Xu, H., & Zhuang, X. (2019) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s208061 · Cited by 83
Antagonism of the 5-HT 6 receptor – Preclinical rationale for the treatment of Alzheimer's disease
de Jong, I. E. M., & Mørk, A. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.07.010 · Cited by 83
Idris, N., Neill, J., Grayson, B., Bang-Andersen, B., Witten, L. M., Brennum, L. T., & Arnt, J. (2010) · Psychopharmacology · doi:10.1007/s00213-009-1702-5 · Cited by 74
“Our studies demonstrate that sertindole, at relevant doses and plasma exposure levels approximating those seen clinically (Rodefer et al. 2008), ameliorates the reversal learning and the episodic memory deficits induced by subchronic PCP.”
BackgroundInfluentialSelf-citationSelective phosphodiesterase inhibitors improve performance on the ED/ID cognitive task in rats
Rodefer, J. S., Saland, S. K., & Eckrich, S. J. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.08.008 · Cited by 77
Self-citationMazindol attenuates ketamine-induced cognitive deficit in the attentional set shifting task in rats
Nikiforuk, A., Gołembiowska, K., & Popik, P. (2009) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2009.08.001 · Cited by 77
Assessment of intradimensional/extradimensional attentional set-shifting in rats
Tait, D. S., Bowman, E. M., Neuwirth, L. S., & Brown, V. J. (2018) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2018.02.013 · Cited by 66
“Indeed, those studies that have directly compared the sexes find no effect of sex on control performance regardless of strain: Lister Hooded (Snigdha et al., 2011); Sprague Dawley (Mohamed et al., 2011); or Long Evans (Murphy et al., 2017).”
BackgroundKołaczkowski, M., Marcinkowska, M., Bucki, A., Pawłowski, M., Mitka, K., Jaśkowska, J., Kowalski, P., Kazek, G., Siwek, A., Wasik, A., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401895u · Cited by 69
Broberg, B. V., Dias, R., Glenthoj, B. Y., & Olsen, C. K. (2008) · Behavioural Brain Research · doi:10.1016/j.bbr.2008.02.020 · Cited by 70
Carli, M., Calcagno, E., Mainolfi, P., Mainini, E., & Invernizzi, R. W. (2010) · Psychopharmacology · doi:10.1007/s00213-010-2065-7 · Cited by 73
“Differences between the effects of conventional and atypical antipsychotics have also been observed in NMDA receptor antagonist-based animal models of cognitive deficits of schizophrenia (Amitai et al. 2007; Bakshi et al. 1994; Baviera et al. 2008; Hoffman et al. 1993; Rodefer et al. 2008) and on spontaneous and dizoc…”
BackgroundThe effects of NMDA receptor antagonists on attentional set-shifting task performance in mice
Kos, T., Nikiforuk, A., Rafa, D., & Popik, P. (2011) · Psychopharmacology · doi:10.1007/s00213-010-2102-6 · Cited by 58
“Several preclinical studies have shown that sertindole reduces or reverses the impairing effects of subchronic PCP treatment (Rodefer et al. 2008; Broberg et al. 2009; Goetghebeur and Dias 2009) and of an acute dose of ketamine (Nikiforuk et al. 2010) in the rat ASST.”
BackgroundMethodInfluentialJenkins, T. A., Harte, M. K., & Reynolds, G. P. (2010) · Neuroscience Letters · doi:10.1016/j.neulet.2010.01.028 · Cited by 57
Redrobe, J. P., Elster, L., Frederiksen, K., Bundgaard, C., de Jong, I. E. M., Smith, G. P., Bruun, A. T., Larsen, P. H., & Didriksen, M. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2593-9 · Cited by 68
Asenapine restores cognitive flexibility in rats with medial prefrontal cortex lesions
Tait, D. S., Marston, H. M., Shahid, M., & Brown, V. J. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1364-8 · Cited by 65
Broberg, B. V., Glenthoj, B. Y., Dias, R., Larsen, D. B., & Olsen, C. K. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1540-5 · Cited by 59
Predictably irrational: assaying cognitive inflexibility in mouse models of schizophrenia
Brigman, J. L. (2010) · Frontiers in Neuroscience · doi:10.3389/neuro.01.013.2010 · Cited by 52
“…Chronic, twice daily (5 mg/kg) × 7 days, +10 days w/d Rodefer et al. (2005) Rat IDS/EDS (tactile/olfactory) Chronic, twice daily (5 mg/kg) × 7 days, +10 days w/d Rodefer et al. (2008) Monkey Detour reaching task Chronic, twice daily (0.3 mg/kg) × 14 days, +7 days w/d Jentsch et al.…”
ResultInfluentialAmitai, N., & Markou, A. (2009) · Psychopharmacology · doi:10.1007/s00213-008-1246-0 · Cited by 50
Barak, S., & Weiner, I. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.03.011 · Cited by 52
“kg) were ineffective in reversing subchronic PCP-induced deficits (Rodefer et al., 2008).”
BackgroundIasevoli, F., Tomasetti, C., Marmo, F., Bravi, D., Arnt, J., & de Bartolomeis, A. (2010) · Psychopharmacology · doi:10.1007/s00213-010-1954-0 · Cited by 52
“2007) and may ameliorate cognitive-like impairment induced by acute or subchronic treatment with phencyclidine in preclinical model of psychosis (Broberg et al. 2009; Rodefer et al. 2008).”
InfluentialSelf-citationNikiforuk, A., & Popik, P. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2487-x · Cited by 52
“In contrast to its beneficial effects on preattentive information processing, quetiapine treatment did not reverse PCP-induced impairments on attention and impulsivity as assessed in the 5-choice serial reaction time task (Amitai and Markou 2009).”
BackgroundResultInfluentialDrug Abuse and Psychosis: New Insights into Drug-induced Psychosis
Ham, S., Kim, T. K., Chung, S., & Im, H. (2017) · Experimental Neurobiology · doi:10.5607/en.2017.26.1.11 · Cited by 57
“Haloperidol was ineffective on cognitive deficits in behavioral tests such as set-shifting task, reversal learning, and novel object recognition in the sub-chronic PIP and KIP models, whereas clozapine was effective on some cognitive symptoms such as reversal learning and novel object recognition [4, 34, 38, 39].”
BackgroundMohler, E. G., Baker, P. M., Gannon, K. S., Jones, S. S., Shacham, S., Sweeney, J. A., & Ragozzino, M. E. (2012) · Psychopharmacology · doi:10.1007/s00213-011-2518-7 · Cited by 46
“The enhancement is comparable to that observed with SB399885 on a reversal learning test (Hatcher et al. 2005) and SB-271046 which attenuates a PCP-induced impairment in set-shifting (Rodefer et al. 2008).”
BackgroundResultPsychopharmacological treatment of schizophrenia: What do we have, and what could we get?
Ellenbroek, B. A. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.03.013 · Cited by 54
Differential effects of 5-HT2A and 5-HT2C receptor blockade on strategy-switching
Baker, P. M., Thompson, J. L., Sweeney, J. A., & Ragozzino, M. E. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2010.12.031 · Cited by 46
“strategy shifting or reversal learning, which may be dissociable among different brain circuitry [44], or neurotransmitter systems [46].”
BackgroundRedrobe, J. P., Jørgensen, M., Christoffersen, C. T., Montezinho, L. P., Bastlund, J. F., Carnerup, M. A., Bundgaard, C., Lerdrup, L., & Plath, N. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3492-7 · Cited by 47
“Our group could not demonstrate an effect with acute risperidone (Goetghebeur and Dias 2009), which is in concordance with the CATIE trial (Keefe et al. 2007), or olanzapine (following acute or 21-day administration; Rodefer et al. 2008).”
BackgroundResultJanhunen, S. K., Svärd, H., Talpos, J., Kumar, G., Steckler, T., Plath, N., Lerdrup, L., Ruby, T., Haman, M., Wyler, R., et al. (2015) · Psychopharmacology · doi:10.1007/s00213-015-3954-6 · Cited by 43
“There are also others reporting the scPCP-induced increase in number of trials to reach criterion at ED shift in male Long-Evans rats at 5 mg/kg of scPCP (Rodefer et al. 2005; Rodefer et al. 2008) and in female Lister Hooded rats at 2 mg/kg of scPCP (McLean et al. 2008).”
BackgroundResultInfluentialVariations in Dysbindin-1 are associated with cognitive response to antipsychotic drug treatment
Scheggia, D., Mastrogiacomo, R., Mereu, M., Sannino, S., Straub, R. E., Armando, M., Managò, F., Guadagna, S., Piras, F., Zhang, F., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04711-w · Cited by 45
Snigdha, S., Idris, N. F., Grayson, B., Shahid, M., & Neill, J. C. (2010) · Psychopharmacology · doi:10.1007/s00213-010-2091-5 · Cited by 45
“…subchronic administration of PCP has been shown to produce cognitive deficits in rodents (Abdul-Monim et al. 2003, 2006, 2007; Egerton et al. 2005; Grayson et al. 2007; Idris et al. 2005a, 2009; McLean et al. 2008, 2009a, b, 2010; Rodefer et al. 2005, 2008; Sircar 2003; Stefani and Moghaddam 2002).”
BackgroundMørk, A., Witten, L. M., & Arnt, J. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1578-4 · Cited by 40
“As previously described, sertindole induced a significant reversal of impairment in extradimensional set shifting, while risperidone was ineffective (Goetghebeur and Dias 2009; Rodefer et al. 2008).”
BackgroundSelf-citationModeling Deficits in Attention, Inhibition, and Flexibility in HAND
Moran, L. M., Booze, R. M., & Mactutus, C. F. (2014) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-014-9539-z · Cited by 40
“Rodent models of schizophrenia often incorporate the extradimensional setshifting task to demonstrate deficits in executive function, which are attenuated by D2 antagonist antipsychotics (McLean et al. 2008; Rodefer et al. 2008; Tait et al. 2009).”
Redrobe, J. P., Bull, S., & Plath, N. (2010) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2010.00146 · Cited by 40
“This treatment regime is in accordance with previous methods (see Egerton et al., 2005; Rodefer et al., 2005, 2008).”
MethodNikiforuk, A., Fijał, K., Potasiewicz, A., Popik, P., & Kos, T. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881113480991 · Cited by 37
“In reference to the paradigms used in the current study, a 5-HT6 antagonist reversed ED set-shifting deficits induced by subchronic PCP treatment (Rodefer et al., 2008).”
MethodThe procognitive effects of 5-HT6 receptor ligands in animal models of schizophrenia
Nikiforuk, A. (2014) · Reviews in the Neurosciences · doi:10.1515/revneuro-2014-0005 · Cited by 37
“Accordingly, the co-administration of inactive doses of the 5-HT2A receptor antagonist M100907 and SB-271046 and/ or SB-399885 reverses MK-801-induced PPI impairments.”
BackgroundKołaczkowski, M., Mierzejewski, P., Bieńkowski, P., Wesołowska, A., & Newman‐Tancredi, A. (2014) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-014-0966-4 · Cited by 34
“Indeed, 5HT6 receptor antagonists are active in models of cognition relevant to psychotic disorders (Arnt and Olsen 2011; Rodefer et al. 2008) as well as in tests of antidepressant-like and anxiolytic activity (Carr et al.”
BackgroundTAAR1 as an emerging target for the treatment of psychiatric disorders
Liu, J., Wu, R., & Li, J. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108580 · Cited by 37
de Bruin, N. M. W. J., Drimmelen, M. V., Kops, M. S., van Elk, J., de Wetering, M. M.-V., & Schwienbacher, I. (2013) · Behavioural Brain Research · doi:10.1016/j.bbr.2013.01.035 · Cited by 39
Antagonism at serotonin 5-HT2A receptors modulates functional activity of frontohippocampal circuit
Gozzi, A., Crestan, V., Turrini, G., Clemens, M., & Bifone, A. (2010) · Psychopharmacology · doi:10.1007/s00213-009-1772-4 · Cited by 33
Marazziti, D., Baroni, S., Pirone, A., Giannaccini, G., Betti, L., Schmid, L., Vatteroni, E., Palego, L., Borsini, F., Bordi, F., et al. (2012) · Neurochemical Research · doi:10.1007/s11064-011-0684-y · Cited by 39
Amitai, N., & Markou, A. (2008) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2008.08.025 · Cited by 43
“…et al., 1959; Yesavage and Freeman, 1979; Pearlson, 1981; Pradhan, 1984) and animals (Handelmann et al., 1987; Stefani and Moghaddam, 2005; Rodefer et al., 2005, 2008; Idris et al., 2003, 2005; Abdul-Monim et al., 2003, 2006, 2007; Depoortère et al., 2007; Didriksen et al., 2007) and…”
BackgroundInfluentialPehrson, A. L., Pedersen, C. S., Tølbøl, K. S., & Sánchez, C. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00162 · Cited by 31
Talpos, J. C., & Shoaib, M. C. (2015) · Handbook of experimental pharmacology · doi:10.1007/978-3-319-16522-6_6 · Cited by 28
5-HT6 Receptor Ligands and their Antipsychotic Potential
Arnt, J., & Olsen, C. K. (2011) · International review of neurobiology · doi:10.1016/b978-0-12-385902-0.00006-1 · Cited by 29
Self-citationPedersen, C. S., Goetghebeur, P., & Dias, R. (2009) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2009.09.014 · Cited by 28
Emerging treatments in the management of schizophrenia – focus on sertindole
Zoccali, R. A. (2010) · Drug Design Development and Therapy · doi:10.2147/dddt.s6591 · Cited by 27
Fellini, L., Kumar, G., Gibbs, S., Steckler, T., & Talpos, J. C. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.08.012 · Cited by 28
“…including reversal learning in an operant environment (Idris et al., 2010, McLean et al., 2009,2010, 2011), although generally not in attentional set-shifting paradigms (McLean et al., 2008, 2012; Pedersen et al., 2009; Rodefer et al., 2005; Rodefer et al., 2008; Egerton et al., 2005, 2008).”
McAllister, K. A. L., Mar, A. C., Theobald, D. E. H., Saksida, L. M., & Bussey, T. J. (2015) · Psychopharmacology · doi:10.1007/s00213-015-4018-7 · Cited by 25
de Bartolomeis, A., Ciccarelli, M., Simone, G. D., Mazza, B., Barone, A., & Vellucci, L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065945 · Cited by 32
Kołaczkowski, M., Mierzejewski, P., Bieńkowski, P., Wesołowska, A., & Newman‐Tancredi, A. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12509 · Cited by 54
“5-HT6 receptor antagonists are also active in a range of models of cognition relevant to psychotic disorders (Loiseau et al., 2008; Rodefer et al., 2008; Arnt and Olsen, 2011) as well as in tests of antidepressant-like and anxiolytic activity (Wesołowska, 2007; Carr et al.”
Nikiforuk, A., Kos, T., Rafa, D., Behl, B., Bespalov, A., & Popik, P. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.04.010 · Cited by 25
Wang, S., Han, C., Lee, S.-J., Patkar, A. A., Masand, P. S., & Pae, C. (2013) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e3182aa38c4 · Cited by 26
“38 Sertindole's 5-HT6 receptor antagonistic activity in the absence of anticholinergic and antihistaminic actions might provide a potential benefit on improving cognitive functions while having lower risk of sedation.(39) Such a potential benefit has been indeed shown in several animal studies.”
BackgroundWood, C., Kohli, S., Malcolm, E. M., Allison, C., & Shoaib, M. C. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.01.006 · Cited by 31
Assessment of cognitive functions in animal models of schizophrenia
Nikiforuk, A. (2018) · Pharmacological Reports · doi:10.1016/j.pharep.2018.01.009 · Cited by 20
Fijał, K., Popik, P., & Nikiforuk, A. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3234-2 · Cited by 25
“Moreover, they enhance cognitive flexibility in the attentional set shifting task (Hatcher et al. 2005; Rodefer et al. 2008), a model used to assess the prefrontal flexibility that is compromised in schizophrenic patients.”
Nirogi, R. V. S., Dwarampudi, A., Kambhampati, R., Bhatta, V., Kota, L., Shinde, A. K., Badange, R. K., Jayarajan, P., Bhyrapuneni, G., & Dubey, P. K. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.05.106 · Cited by 23
5-HT6 receptor agonist EMD386088 impairs behavioral flexibility and working memory
Amodeo, D. A., Peterson, S., Pahua, A. E., Posadas, R., Hernandez, A., Hefner, E., Qi, D., & Vega, J. (2018) · Behavioural Brain Research · doi:10.1016/j.bbr.2018.04.032 · Cited by 27
Serotonin Receptors of Type 6 (5-HT6): What can we Expect from them?
Marazziti, D., Baroni, S., Dell’Osso, M. C., Bordi, F., & Borsini, F. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711796011283 · Cited by 27
Beninger, R. J., Beuk, J., Banasikowski, T. J., van Adel, M., Boivin, G. A., & Reynolds, J. N. (2010) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e3283347091 · Cited by 26
“…discrimination, and set shifting) have similarly reported deficits after subchronic PCP (Rodefer et al., 2005; Abdul-Monim et al., 2006, 2007; Dunn and Killcross 2006; Fujita et al., 2008; Hagiwara et al., 2008; Hashimoto et al., 2008a, b; Rodefer et al., 2008; McLean et al., 2008, 2009a, b).”
BackgroundWallace, J., Marston, H. M., McQuade, R., & Gartside, S. E. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.12.005 · Cited by 26
“The dosing regimen is that previously used by Rodefer et al. (2005, 2008) however, given that PCP has a half-life of less than 4 h in male rats (Shelnutt et al., 1999) we shortened the washout time to 72 h.”
MethodResultCarli, M., Calcagno, E., Mainini, E., Arnt, J., & Invernizzi, R. W. (2011) · Psychopharmacology · doi:10.1007/s00213-010-2066-6 · Cited by 20
“2007) and reverse cognitive deficits induced by acute or subchronic PCP in rats such as Morris’ water maze test, and in tests of reversal learning, object recognition and attentional set shifting (Didriksen et al. 2007; Idris et al. 2010; Rodefer et al. 2008).”
BackgroundMethodResultInfluentialSelf-citationSynthesis and SAR of tolylamine 5-HT6 antagonists
Singer, J. M., Wilson, M. W., Johnson, P. D., Graham, S. R., Cooke, L. W., Roof, R. L., Boxer, P. A., Gold, L. H., Meltzer, L. T., Janssen, A. M., et al. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.03.077 · Cited by 19
Livingston, N. R., Hawkins, P. C., Gilleen, J., Ye, R., Valdearenas, L., Shergill, S. S., & Mehta, M. A. (2021) · Journal of Psychopharmacology · doi:10.1177/02698811211000778 · Cited by 17
“, 2009), serotonin receptor antagonists (Rodefer et al., 2008) and dopamine agonists (Fletcher et al.”
BackgroundDunn, A. L., Michie, P. T., Hodgson, D. M., & Harms, L. R. (2020) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.06.028 · Cited by 18
Strategies for pharmacotherapy of schizophrenia
Arnt, J., Bang‐Andersen, B., Dias, R. D. S., & Bøgesø, K. P. (2008) · Drugs of the Future · doi:10.1358/dof.2008.033.09.1236966 · Cited by 17
Self-citationEmerging role of sertindole in the management of schizophrenia
Rodefer, J. S., & Cincotta (2010) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s7602 · Cited by 18
Self-citationAntipsychotics and the Dopamine–Serotonin Connection
Ellenbroek, B. A., & Cesura, A. M. (2014) · Topics in medicinal chemistry · doi:10.1007/7355_2014_51 · Cited by 21
“Especially 5-HT6 receptor antagonists have been found to show cognitive enhancing effects in rodent models [209–211].”
BackgroundNikiforuk, A., Potasiewicz, A., Rafa, D., Drescher, K. U., Bespalov, A., & Popik, P. (2015) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000201 · Cited by 16
“Accordingly, atypical antipsychotics, including clozapine, olanzapine and risperidone, were largely ineffective in normalizing setshifting deficits in preclinical schizophrenia models (Rodefer et al., 2008; Goetghebeur and Dias, 2009).”
BackgroundTacrine improves reversal learning in older rats
Tait, D. S., Chase, E. A., & Brown, V. J. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.05.036 · Cited by 15
Sertindole in schizophrenia: efficacy and safety issues
Muscatello, M. R. A., Bruno, A., Bellinghieri, P. M., Pandolfo, G., & Zoccali, R. A. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.947960 · Cited by 16
Drug safety and efficacy evaluation of sertindole for schizophrenia
Karamatskos, E., Lambert, M., Mulert, C., & Naber, D. (2012) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2012.726984 · Cited by 14
Efficacy and Safety of Sertindole in Schizophrenia: A Clinical Review
Zoccali, R. A., Bruno, A., & Muscatello, M. R. A. (2015) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000305 · Cited by 13
Attentional Set‐Shifting Paradigm in the Rat
Popik, P., & Nikiforuk, A. (2015) · Current Protocols in Neuroscience · doi:10.1002/0471142301.ns0951s72 · Cited by 14
“Subchronic phencyclidine regimes have been also widely employed to impair ED shifting in the rat (Egerton et al., 2008; McLean et al., 2008; Rodefer et al., 2008; Goetghebeur and Dias, 2009).”
BackgroundEnvironmental enrichment ameliorates phencyclidine-induced cognitive deficits
Saland, S. K., & Rodefer, J. S. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.02.014 · Cited by 14
“Givenpreviousfindings that EDSproblems aremore difficult to solve compared to IDS problems (Barense et al., 2002; Fox et al., 2003;Rodefer et al., 2005, 2008), we first assessed the validity of the cognitive set in saline-treated control animals using a paired t test.”
BackgroundMethodResultSelf-citationSertindole for the treatment of schizophrenia
Azorin, J., Kaladjian, A., Fakra, É., & Adida, M. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2010.536217 · Cited by 11
“The low affinity of sertindole for muscarinic cholinergic and histamine H1-receptors, in association with its high affinity for 5HT6receptors [30,31], may be responsible for its beneficial effect on cognition, as evidenced in both animal models [41-44] and clinical studies [61,68].”
BackgroundResultBehavioral and Neurochemical Pharmacology of 5-HT6 Receptors Related to Reward and Reinforcement
Chiara, G. D., Valentini, V., & Fenu, S. (2011) · International review of neurobiology · doi:10.1016/b978-0-12-385902-0.00005-x · Cited by 13
Metadata
- Authors
- Rodefer, J. S., Nguyen, T. N., Karlsson, J.-J., & Arnt, J.
- Affiliations
- University of Iowa (US)
- Lundbeck (Denmark) (DK)
- Corresponding author
- Rodefer, Joshua S
- ORCID
- Rodefer, Joshua S
- Venue
- Neuropsychopharmacology
- Published
- 2007-12-19
- Volume
- 33
- Issue
- 11
- Pages
- 2657-2666
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- OpenAlex
- W2140390949
- Cited by
- 126
- References
- 64
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 3 · 2023: 3 · 2022: 2 · 2021: 3 · 2020: 1 · 2019: 2 · 2018: 7 · 2017: 5 · 2016: 1 · 2015: 13 · 2014: 9 · 2013: 9 · 2012: 7
- FWCI
- 8.07
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Neuropsychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- H. Lundbeck A/S
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacological Receptor Mechanisms and Effects
- Keywords
- schizophrenia, cognitive impairment, set-shifting, executive function, sertindole, 5-HT6 receptor antagonists, phencyclidine, haloperidol, atypical antipsychotics, risperidone, clozapine, olanzapine, M100907, 5-HT2A receptor antagonist, antimuscarinic activity
- MeSH terms
- Animals, Attention, Imidazoles, Indoles, Male, Phencyclidine, Receptors, Serotonin, Serotonin Antagonists, Antipsychotic Agents, Rats, Long-Evans, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.